Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics...
Transcript of Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics...
![Page 1: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/1.jpg)
Division of Molecular Therapeutics and Formulation
School of Pharmacy, University of Nottingham
Vectura Group plc
Alejandro Nieto-Orellana
![Page 2: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/2.jpg)
Protein Therapeutics
2http://ww1.prweb.com/prfiles/2011/06/14/8893206/biosimilar_injectable.jpg
![Page 3: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/3.jpg)
Protein Therapeutics
3
http://www.vectura.com/technologies/device-technologies/
![Page 4: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/4.jpg)
4
Pulmonary protein delivery: challenges
https://aapsblog.aaps.org
http://nanogloss.com/tag/white-light-nanoparticles/#axzz4RlvVAXno`
http://i.ndtvimg.com/i/2015-12/lungs-generic_650x400_51450598122.jpg
![Page 5: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/5.jpg)
5
Pulmonary protein delivery: challenges
![Page 6: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/6.jpg)
Polymer-based Nanosystems
6
![Page 7: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/7.jpg)
Polymer-based Nanosystems
7
-- - -
![Page 8: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/8.jpg)
8
Polymer-protein nanocomplexes
N3H+
+
https://www.quora.com/Why-are-protein-structures-represented-by-a-ribbon-cartoon
![Page 9: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/9.jpg)
Copolymers used in this study
9
![Page 10: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/10.jpg)
Copolymers used in this study
10
![Page 11: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/11.jpg)
Formation of polymer-protein nanocomplexes
11
0 2 0 0 4 0 0 6 0 0 8 0 0
0 .0
0 .5
1 .0
1 .5 L 1 0 -L y s
H y d ro d y n a m ic d ia m e te r (n m )
Co
nc
en
tra
tio
n
(E6
pa
rtic
le/m
l)
0 2 0 0 4 0 0 6 0 0 8 0 0
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5 L 3 0 -L y s
H y d ro d y n a m ic d ia m e te r (n m )
Co
nc
en
tra
tio
n
(E6
pa
rti
cle
/ml)
0 2 0 0 4 0 0 6 0 0 8 0 0
0
1
2
3
4 M 3 0 -L y s
H y d ro d y n a m ic d ia m e te r (n m )
Co
nc
en
tra
tio
n
(E6
pa
rti
cle
/ml)
0 2 0 0 4 0 0 6 0 0 8 0 0
0
1
2
3
4
5 M 9 0 -L y s
H y d ro d y n a m ic d ia m e te r (n m )
Co
nc
en
tra
tio
n
(E6
pa
rti
cle
/ml)
109 ± 61 nm 146 ± 42 nm
183 ± 111 nm 159 ± 158 nm
![Page 12: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/12.jpg)
Formation of dry powders from nanocomplexes suspension
12
µ
![Page 13: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/13.jpg)
Ly
s
L1
0-L
ys
L3
0-L
ys
M3
0-L
ys
M9
0-L
ys
0
2 0
4 0
6 0
8 0
1 0 0
E m it te d d o s e
ED
(%
)
Lys
L10-L
ys
L30-L
ys
M30-L
ys
M90-L
ys
0
2 0
4 0
6 0
8 0
1 0 0
F in e P a r t ic le F ra c t io n
FP
F (
%)
Aerosol properties of the different dry powders
13
![Page 14: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/14.jpg)
Recovery of nanocomplexes from dry powder
formulations
14
0 2 0 0 4 0 0 6 0 0
0
2 0
4 0
6 0
8 0
1 0 0
N a n o c o m p le x e s B E F O R E fo rm u la tio n
in to d ry p o w d e rs
H y d ro d y n a m ic d ia m e te r (n m )
No
rm
ali
se
d P
arti
cle
Co
nc
en
tra
tio
n
0 2 0 0 4 0 0 6 0 0
0
2 0
4 0
6 0
8 0
1 0 0
N a n o c o m p le x e s R E C O V E R E D
fro m d ry p o w d e rs
H y d ro d y n a m ic d ia m e te r (n m )
No
rm
ali
se
d P
arti
cle
Co
nc
en
tra
tio
nL 1 0 -L y s
L 3 0 -L y s
M 3 0 -L y s
M 9 0 -L y s
![Page 15: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/15.jpg)
Lys
L10-L
ys
L30-L
ys
M30-L
ys
M90-L
ys
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
E n z y m a tic a c tiv ity A F T E R
n a n o c o m p le x e s d is s a s e m b ly
No
rm
ali
se
d
en
zy
ma
tic
ac
tiv
ity
(%
)
Recovery of nanocomplexes from dry powder
formulations
15
Lys
L10-L
ys
L30-L
ys
M30-L
ys
M90-L
ys
0
2 0
4 0
6 0
8 0
1 0 0
E n z y m a tic a c tiv ity o f
n a n o c o m p le x e s
No
rm
ali
se
d
en
zy
ma
tic
ac
tiv
ity
(%
)
![Page 16: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/16.jpg)
Protection against proteolytic degradation
16
Lys
L10-L
ys
L30-L
ys
M30-L
ys
M90-L
ys
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
P ro te in p ro te c tio n
No
rma
lis
ed
en
zy
ma
tic
ac
tiv
ity
(%
)
****
![Page 17: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/17.jpg)
Immunogenicity
17
Lys
L30-L
ys
M30-L
ys
0
2 0
4 0
6 0
Co
mp
lem
en
t a
cti
va
tio
n (
%)
****
![Page 18: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/18.jpg)
18
![Page 19: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/19.jpg)
19
![Page 20: Alejandro Nieto-Orellana - The Aerosol Society · 2019-03-15 · Division of Molecular Therapeutics and Formulation School of Pharmacy, University of Nottingham Vectura Group plc](https://reader033.fdocuments.in/reader033/viewer/2022042112/5e8d96de1cef4340a93ce860/html5/thumbnails/20.jpg)
THANK YOU FOR YOUR ATTENTION
Alejandro Nieto-Orellana